Neuroproteins-stroke

2025 Activity indicators

5 competitive national public projects: ISCIII, MICINN/MINECO, CAM

3 private projects led
13 clinical studies led
2 competitive HR contracts
21 publications
FI: 108.20
Publications in Q1: 16 (76%)
Publications in D1: 9 (43%)
1 supervised doctoral thesis defended
Public agency evaluators: 3 PIs
Editorial committee members: 2 PIs
6 active patent families:
- 1 internationally extended patent family in 11 countries, protecting the use of steronitrons in neurodegenerative diseases (PCT/ES2014/070421)
- 1 patent application to protect new quinolylnitron compounds PCT/EP2019/077525, extended in the US and EU
- 1 new patent for new steronitron compounds with priority European application EP20382158 and PCT/ EP2021/055653, extended in the US and EU
- 1 application for a nitrone-type compound in stroke with European application EP22382680
- 1 application for a nitrone-type compound in deafness, with European application EP22382706.4 and PCT/EP2023/070340
1 visiting researcher hosted for a stay of less than 2 months: Polytechnic University of Madrid

Milestones

Important work on a new therapeutic mechanism of action for neuroprotection in cerebral ischemia: Martínez E, Escobar A, Di F, Cavalli A, Alcázar A. ISQ201, a neuroprotective agent in ischemic stroke, is a novel activator of protein synthesis via allosteric binding to translation factor eIF4E. Int. J. Biol. Macromol. 2025;328(Pt 1): 147400 - 147400. DOI:10.1016/j.ijbiomac.2025.147400.
Important study of critical thrombus migration in patients treated with oral anticoagulants: García G, Moreno C, López R, Lorenzo P, Garay P, Martínez B, Llanes A, Pérez D, Chico JL, Vera R, García S, Matute C, de Felipe A, Masjuan J, Cruz A. Clot migration in patients treated with tenecteplase versus alteplase before mechanical thrombectomy. Eur. Stroke J. 23969873241263201. DOI:10.1177/23969873241263201.
Original publication of a new damage mechanism in cerebral ischemia: Carretero VJ, Álvarez I, Hernández J, Kirov SA, Hernández JM. Targeting harmful effects of non-excitatory amino acids as an alternative therapeutic strategy to reduce ischemic damage. Neural Regen. Res. 2025;20(9): 2454 - 2463. DOI:10.4103/NRR.NRR-D-24-00536.
Interesting study that identifies biomarkers in thrombi that differentiate the etiology in stroke: Peracho L, Martínez E, Bermúdez I, Cruz A, de Felipe A, Fandiño E, García S, Matute MC, Méndez JC, Vera R, Masjuan J, Alcázar A. Identification of Differential Proteins in Thrombi of Cardioembolic and Atherothrombotic Etiology in Patients with Ischemic Stroke. Int. J. Mol. Sci. 2025;26(17): 8333. DOI:10.3390/ijms26178333.
Alejandro Escobar's doctoral thesis on the preclinical characterization of ISQ201, a neuroprotective compound developed by the group. Thesis supervised by Dr. Emma Martínez and Dr. Alberto Alcázar.

Bibliometrics

	Articles	Accum. FI	Mean IF	Articles Q1 or Q2	% in Q1 or Q2	Articles D1	% in D1
2021	35	178.39	5.20	20	57	7	20
2022	25	426.05	18.52	19	76	6	24
2023	24	141.52	7.06	17	71	6	25
2024	19	104.50	5.50	19	100	7	37
2025	21	108.20	5.70	20	95	9	43
	124	958.66	8.40	95	80	35	30